Grace Lee is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1100 9th Ave
Seattle, WA 981012756
Telephone
206-223-6624Registry record last updated 23 Dec 2014.
Clinical trials
- Anti-VEGF Therapy for Acute Thyroid Eye Disease
Sponsor: Massachusetts Eye and Ear Infirmary
- Impact of Metformin on Immunity
Sponsor: The University of Texas Health Science Center at San Antonio
- Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy
Sponsor: University of Michigan Rogel Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ascendis Pharma Endocrinology IncProgram year20251 payment
- PFIZER INC.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
43.1%l-Thyroxine36%Levothyroxine Sodium83%Synthroid17%Part D≥76 patientsThyroid Hormone Synthesis Inhibitor3.4%Methimazole100%Part D≥12 patients+ 3 more classes in this area
Metabolism & gastrointestinal
41.7%Insulin Analog15%Lantus Solostar33%Humalog Kwikpen U-10021%Novolog13%Tresiba Flextouch U-10010%Basaglar Kwikpen U-10010%Lantus7%Humalog7%Part D<11 patientsGLP-1 receptor agonist11%Mounjaro90%Ozempic10%Part D<11 patients+ 6 more classes in this area
Cardiovascular
9.2%Statin3.5%Atorvastatin Calcium59%Rosuvastatin Calcium41%Part D<11 patientsAngiotensin receptor blocker (ARB)2.3%Losartan Potassium100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”